Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Glucagon Receptor Signaling and Lipid Metabolism

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Development and Feasibility of a Regulated, Supramaximal High-Intensity Training Program Adapted for Older Individuals

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Muscle Activation During ACL Injury Risk Movements in Young Female Athletes: A Narrative Review

    Research output: Contribution to journalReviewResearchpeer-review

  3. Brugada Syndrome-Associated Genetic Loci Are Associated With J-Point Elevation and an Increased Risk of Cardiac Arrest

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The Liver-α-Cell Axis and Type 2 Diabetes

    Research output: Contribution to journalReviewResearchpeer-review

  3. Endogenous glucose-dependent insulinotropic polypeptide exerts diverging and tissue specific in obese patients with type 2 diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  4. The glucagon-like peptide-1 receptor agonist, liraglutide, does not suppress postprandial cholecystokinin in patients with type 1 diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

View graph of relations

Glucagon is secreted from the pancreatic alpha cells upon hypoglycemia and stimulates hepatic glucose production. Type 2 diabetes is associated with dysregulated glucagon secretion, and increased glucagon concentrations contribute to the diabetic hyperglycemia. Antagonists of the glucagon receptor have been considered as glucose-lowering therapy in type 2 diabetes patients, but their clinical applicability has been questioned because of reports of therapy-induced increments in liver fat content and increased plasma concentrations of low-density lipoprotein. Conversely, in animal models, increased glucagon receptor signaling has been linked to improved lipid metabolism. Glucagon acts primarily on the liver and by regulating hepatic lipid metabolism glucagon may reduce hepatic lipid accumulation and decrease hepatic lipid secretion. Regarding whole-body lipid metabolism, it is controversial to what extent glucagon influences lipolysis in adipose tissue, particularly in humans. Glucagon receptor agonists combined with glucagon-like peptide 1 receptor agonists (dual agonists) improve dyslipidemia and reduce hepatic steatosis. Collectively, emerging data support an essential role of glucagon for lipid metabolism.

Original languageEnglish
Article number413
JournalFrontiers in physiology
Volume10
Issue numberAPR
Pages (from-to)1-11
Number of pages11
ISSN1664-042X
DOIs
Publication statusPublished - Apr 2019

    Research areas

  • Adipose tissue, Alpha cell, Glucagon, Lipid, Liver

ID: 57549192